Convoy Therapeutics Announces Publication of Further Research Studies With SPACETM Technology Platform
Oro Valley, Arizona (PRWEB) November 13, 2014 -- In the first study, the company and its colleagues extrapolated on their prior work published in 2011 in Proceedings of the National Academy of Sciences, using silencing RNA (siRNA) with its technology. The recent study further demonstrates the ability of SPACETM platform technology to enhance penetration of siRNA into skin and induce significant target knockdown.
The most recent paper, “Topical delivery of hyaluronic acid into skin using SPACE peptide carriers,” describes the work of Convoy Therapeutics and the team of researchers at University of California at Santa Barbara to demonstrate significant penetration of hyaluronic acid molecules in all skin layers, and most importantly for skin matrix regeneration, into the epidermis, using the company’s SPACETM technology platform. The study demonstrates the platform successfully delivers significant amounts of large molecular weight (250-300kDa) hyaluronic acid into skin. The larger molecular weight hyaluronic acid is more beneficial than lower mass molecules due to its ability to induce skin matrix regeneration; however these large molecules typically do not penetrate independently.
"These seminal results further validate the flexibility of our SPACETM platform technology and indicate that we are at the forefront of being able to consistently deliver therapeutic molecules that were not previously used in topical applications due to their inability to penetrate. Using this platform, Convoy Therapeutics can address the unmet needs in topical dermatology,” says John Muraski, President and CEO of Convoy Therapeutics.
About Convoy Therapeutics
Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology allows large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised for internal clinical development.
Debbie Rinaldi, Director Business Development, Convoy Therapeutics, http://www.convoytx.com, +1 702.448.1826, [email protected]
Share this article